PRESS RELEASES

Found 232 Results
Page 1 of 24

Onxeo Enters into Settlement Agreement with SpePharm and SpeBio


Settlement agreement fully resolves long-lasting litigation between the parties and all related proceedings Settlement terms have no impact on Onxeo’s […]

02/11/2020


“La France bouge” – Europe 1 : Interview of Judith Greciet


(in French only)   Watch the interview  

02/04/2020


Onxeo Enters Clinical Research Agreement with Gustave Roussy to Conduct Clinical Trial of AsiDNA™ for Treatment of Relapsed Ovarian Cancer


The REVOCAN phase 1b/2 study, sponsored by Gustave Roussy, will evaluate the effect of AsiDNA™ on the acquired resistance to […]

01/29/2020


Onxeo to Present Next-Generation PARP inhibitor, OX401, at PARP & DDR Inhibitors Summit 2020


Paris (France), January 28, 2020 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

01/28/2020


Onxeo Publishes Shareholder Newsletter


Paris (France), January 20, 2020 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

01/20/2020



Onxeo Announces its Financial Agenda for 2020


  Paris (France), December 9, 2019 – 05:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or […]

12/09/2019


Onxeo Announces Publication of Preclinical Study Results Comparing Efficacy and Toxicity of olaparib and AsiDNA™ in Frontiers in Oncology


In-vivo Models Showed that Only AsiDNA™ Could Delay Resistance to Carboplatin without Increasing its Toxicity Paris (France), November 13, 2019 […]

11/13/2019



Onxeo to attend the European Healthcare Conference organized by Bryan, Garnier & Co.


Paris (France), November 5, 2019 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Tags:

11/05/2019


Page 1 of 24

Last updated on